Ipsogen, Qiagen deal

Qiagen acquired a 61% stake in blood cancer diagnostic company Ipsogen for €12.90 per share or about €39.9 million ($56.4 million) based on 5.1 million shares outstanding. The price is a 71% premium to Ipsogen's close of €7.55 on June 13, the last trading day before the Qiagen announced its plans to acquire Ipsogen for about €70 million ($99 million) in cash. Qiagen said it will acquire the remaining 39% at the same price through a public tender offer (see BioCentury, June 20). ...